A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

Article Abstract:

Recipients of bone marrow transplants who take fluconazole may develop fewer fungal infections. Patients who receive bone marrow transplants are often vulnerable to fungal infections because their immune systems are suppressed. Out of 356 bone marrow transplant patients, 179 received 400 milligrams (mg) of oral fluconazole daily, and 177 received 400 mg each day of a placebo, an inactive substance. By the end of treatment, 29.6% of the patients treated with fluconazole had fungal infections compared to 67.2% of the patients who received placebo. Fifteen (8.4%) patients in the fluconazole group had superficial fungal infections and five (2.8%) had fungal infections in the blood. Fifty-nine (33.3%) patients in the placebo group had superficial fungal infections, and 28 (15.8%) had fungal infections in the blood. The number of patients who died within 90 days of treatment was the same for both groups. But only one patient in the fluconazole group died from a fungal infection, compared to 10 patients in the placebo group.

Health aspects, Bone marrow, Bone marrow transplantation

---

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection

Article Abstract:

Fluconazole may be more effective than clotrimazole in preventing fungal infections in HIV-infected patients. Of 428 patients with advanced HIV infection, 217 began taking 200 milligrams (mg) of fluconazole a day and 211 took five 10 mg clotrimazole lozenges a day to prevent oral candida infections, systemic cryptococcal infections, histoplasma infections and other fungal infections. They were followed until they developed a fungal infection. Four percent of the patients taking fluconazole developed a fungal infection compared to 11% of those taking clotrimazole. The reduction in cryptococcal infections was most pronounced, but few patients developed other fungal infections. Patients with CD4 T cell counts of 50 or less were most likely to benefit from fluconazole.

Evaluation, Cryptococcal infections, Cryptococcosis, Thrush (Mouth disease), Oral candidiasis, Clotrimazole

---

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Article Abstract:

A randomized, multicenter study compares the efficacy and safety of posaconazole with those of fluconazole or itraconazole as prophylaxis for patients with prolonged neutropenia. Evidence suggests that in patients undergoing chemotherapy for acute myelogenous leukemia or the myelo-dysplastic syndrome, posaconazole prevents invasive fungal infections more effectively and improves overall survival.

United States, Drug therapy, Comparative analysis, Acute myelocytic leukemia, Posaconazole (Medication)

Similar abstracts:

• Abstracts: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogenic bone marrow transplantation
• Abstracts: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
• Abstracts: A controlled trial of two acellular vaccines and one whole cell vaccine against pertussis. Survival of zidovudine-treated patients with AIDS compared to that of contemporary untreated patients
• Abstracts: Prevention tries to break into medicine's mainstream. Students: Give us primary care incentives, not coercion
• Abstracts: Physicians have always offered free health care to needy. The case for educated managers - and physicians. Keep physicians in control of contracting, teaching

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.